Literature DB >> 27596006

Activated CD4+ and CD8+ T Cell Proportions in Multiple Sclerosis Patients.

Borros Arneth1,2.   

Abstract

The goal of this study was to trace the course of multiple sclerosis (MS) by evaluating the lymphocyte subpopulation counts and the levels of CD4+ and CD8+ T cell activation using flow cytometry. Samples obtained from healthy subjects (N = 40) and patients with MS (N = 290) were analyzed. Lymphocytes were labeled for the surface markers CD4+, CD8+, CD3+, CD16+, CD19+, CD45+, and CD53+ and the activation marker HLA-DR+. Cell counts were then determined using flow cytometry. A high degree of inter-individual variability was observed in the counts of all lymphocyte subtypes in the MS group. A significantly lower proportion of CD3+ T cells (69 ± 14 % in healthy subjects and 60 ± 17 % as a percent of total lymphocytes in MS patients), CD4+ T cells (41 ± 11 and 28 ± 18 %, respectively), and a significantly higher proportion of NK T cells (12 ± 5 and 25 ± 21 %, respectively) were observed in patients with MS than in healthy subjects. These differences led to a lowered CD4+/CD8+ T cell ratio. Furthermore, a significantly lower proportion of activated CD4+ T cells (HLA-DR+ CD4+; from 48 ± 10 to 38 ± 15 % as a percent of CD4+ cells) was observed in patients with MS than in healthy subjects. The high level of inter-individual variability in lymphocyte cell counts and the counts of activated T cells suggest that MS is a complex and heterogeneous disease.

Entities:  

Keywords:  CD4+ T helper cells; CD8+ cytotoxic T cells; T lymphocytes; multiple sclerosis

Mesh:

Substances:

Year:  2016        PMID: 27596006     DOI: 10.1007/s10753-016-0441-0

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  17 in total

1.  Newly produced T and B lymphocytes and T-cell receptor repertoire diversity are reduced in peripheral blood of fingolimod-treated multiple sclerosis patients.

Authors:  M Chiarini; A Sottini; D Bertoli; F Serana; L Caimi; S Rasia; R Capra; L Imberti
Journal:  Mult Scler       Date:  2014-11-12       Impact factor: 6.312

2.  GATA-3 expression is controlled by TCR signals and regulates CD4/CD8 differentiation.

Authors:  Gabriela Hernández-Hoyos; Michele K Anderson; Chi Wang; Ellen V Rothenberg; Jose Alberola-Ila
Journal:  Immunity       Date:  2003-07       Impact factor: 31.745

3.  Modulation of CNS autoimmune responses by CD8(+) T cells coincides with their oligoclonal expansion.

Authors:  Henrike J Fischer; Jens van den Brandt; Thomas Lingner; Francesca Odoardi; Alexander Flügel; Andreas Weishaupt; Holger M Reichardt
Journal:  J Neuroimmunol       Date:  2015-10-29       Impact factor: 3.478

4.  The dominant source of CD4+ and CD8+ T-cell activation in HIV infection is antigenic stimulation.

Authors:  J W Cohen Stuart; M D Hazebergh; D Hamann; S A Otto; J C Borleffs; F Miedema; C A Boucher; R J de Boer
Journal:  J Acquir Immune Defic Syndr       Date:  2000-11-01       Impact factor: 3.731

5.  Comparing the kinetics of NK cells, CD4, and CD8 T cells in murine cytomegalovirus infection.

Authors:  Timothy E Schlub; Joseph C Sun; Senta M Walton; Scott H Robbins; Amelia K Pinto; Michael W Munks; Ann B Hill; Laurent Brossay; Annette Oxenius; Miles P Davenport
Journal:  J Immunol       Date:  2011-06-22       Impact factor: 5.422

6.  High interindividual variability in the CD4/CD8 T cell ratio and natalizumab concentration levels in the cerebrospinal fluid of patients with multiple sclerosis.

Authors:  A Harrer; G Pilz; P Wipfler; K Oppermann; J Sellner; W Hitzl; E Haschke-Becher; S Afazel; T Rispens; D van der Kleij; E Trinka; J Kraus
Journal:  Clin Exp Immunol       Date:  2015-04-27       Impact factor: 4.330

7.  Compositional changes of B and T cell subtypes during fingolimod treatment in multiple sclerosis patients: a 12-month follow-up study.

Authors:  Nele Claes; Tessa Dhaeze; Judith Fraussen; Bieke Broux; Bart Van Wijmeersch; Piet Stinissen; Raymond Hupperts; Niels Hellings; Veerle Somers
Journal:  PLoS One       Date:  2014-10-31       Impact factor: 3.240

Review 8.  CD8(+) T-Cells as Immune Regulators of Multiple Sclerosis.

Authors:  Sushmita Sinha; Alexander W Boyden; Farah R Itani; Michael P Crawford; Nitin J Karandikar
Journal:  Front Immunol       Date:  2015-12-10       Impact factor: 7.561

9.  Early activation of CD4+ and CD8+ T lymphocytes by myelin basic protein in subjects with MS.

Authors:  Borros Arneth
Journal:  J Transl Med       Date:  2015-11-02       Impact factor: 5.531

10.  Influence of fingolimod on basic lymphocyte subsets frequencies in the peripheral blood of multiple sclerosis patients - preliminary study.

Authors:  Julia Rudnicka; Michał Czerwiec; Ewelina Grywalska; Dorota Siwicka-Gieroba; Monika Walankiewicz; Agnieszka Grafka; Michał Zgurski; Agata Surdacka; Halina Bartosik-Psujek; Jacek Roliński
Journal:  Cent Eur J Immunol       Date:  2015-10-15       Impact factor: 2.085

View more
  4 in total

1.  Integration of Genetic and Immune Infiltration Insights into Data Mining of Multiple Sclerosis Pathogenesis.

Authors:  Xiaoyun Zhang; Ying Song; Xiao Chen; Xiaojia Zhuang; Zhiqiang Wei; Li Yi
Journal:  Comput Intell Neurosci       Date:  2022-06-27

Review 2.  Protective and Regenerative Roles of T Cells in Central Nervous System Disorders.

Authors:  Frances L Evans; Marie Dittmer; Alerie G de la Fuente; Denise C Fitzgerald
Journal:  Front Immunol       Date:  2019-09-12       Impact factor: 7.561

3.  Reference ranges of T lymphocyte subsets by single-platform among healthy population in southwest China.

Authors:  Bin Wei; Ying Guo; Liangjun Zhang; Huixiu Zhong; Qiang Miao; Lin Yan; Yangjuan Bai; Weihua Feng; Weiping Liu; Qian Niu; Yi Li
Journal:  BMC Immunol       Date:  2021-12-20       Impact factor: 3.615

4.  Cellular Immune Function in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).

Authors:  Jacqueline M Cliff; Elizabeth C King; Ji-Sook Lee; Nuno Sepúlveda; Asia-Sophia Wolf; Caroline Kingdon; Erinna Bowman; Hazel M Dockrell; Luis Nacul; Eliana Lacerda; Eleanor M Riley
Journal:  Front Immunol       Date:  2019-04-16       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.